• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.

    3/2/26 11:57:56 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Gossamer Bio, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    02/23/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    683 Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,331,304.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,331,304.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,331,304.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.23 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    683 Capital Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,331,304.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,331,304.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,331,304.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.23 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Ari Zweiman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,331,304.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,331,304.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,331,304.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.23 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Gossamer Bio, Inc.
    (b)Address of issuer's principal executive offices:

    3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CALIFORNIA 92121
    Item 2. 
    (a)Name of person filing:

    683 Capital Management, LLC 683 Capital Partners, LP Ari Zweiman
    (b)Address or principal business office or, if none, residence:

    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, New York 10019.
    (c)Citizenship:

    683 Capital Management, LLC - DELAWARE 683 Capital Partners, LP - DELAWARE Ari Zweiman - UNITED STATES
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    38341P102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 2, 2026, 683 Capital Partners, LP beneficially owned 8,000,000 shares of Common Stock and warrants to purchase 4,331,304 shares of Common Stock which are currently exercisable. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 8,000,000 shares of Common Stock and warrants to purchase 4,331,304 shares of Common Stock beneficially owned by 683 Capital Partners, LP. Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 8,000,000 shares of Common Stock and warrants to purchase 4,331,304 shares of Common Stock beneficially owned by 683 Capital Management, LLC. The following percentage is based on 231,456,247 shares of common stock ($0.0001 par value) outstanding as of October 31, 2025, as disclosed in the Issuer's Form 10-Q filed on November 5, 2025, plus 4,331,304 shares of Common Stock issuable upon exercise of currently exercisable warrants held by the Reporting Persons. As of March 2, 2026, the Reporting Persons may be deemed to have beneficially owned approximately 5.23% of the outstanding Common Shares.
    (b)Percent of class:

    5.23  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit A.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    683 Capital Management, LLC
     
    Signature:Ari Zweiman
    Name/Title:Managing Member
    Date:03/02/2026
     
    683 Capital Partners, LP
     
    Signature:Ari Zweiman
    Name/Title:Authorized Person
    Date:03/02/2026
     
    Ari Zweiman
     
    Signature:Ari Zweiman
    Name/Title:Self
    Date:03/02/2026
    Exhibit Information

    JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of Common Stock, par value $0.0001 per share, of Gossamer Bio, Inc. dated as of March 2, 2026 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended. Dated: March 2, 2026 683 CAPITAL MANAGEMENT, LLC By: /s/ Ari Zweiman Ari Zweiman, Managing Member 683 CAPITAL PARTNERS, LP By: /s/ Ari Zweiman Ari Zweiman, Authorized Person /s/ Ari Zweiman Ari Zweiman

    Get the next $GOSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    1/28/2026$9.00Overweight
    Barclays
    9/10/2025$9.00Neutral → Buy
    UBS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    6/25/2024$9.00Outperform
    Oppenheimer
    4/5/2024$4.00Outperform
    Wedbush
    More analyst ratings

    $GOSS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.

    SCHEDULE 13G - Gossamer Bio, Inc. (0001728117) (Subject)

    3/2/26 11:57:56 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Gossamer Bio, Inc. (0001728117) (Filer)

    2/23/26 8:30:24 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Gossamer Bio Inc.

    S-3ASR - Gossamer Bio, Inc. (0001728117) (Filer)

    1/28/26 4:01:24 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective January 5th, 2026, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The award was granted as an indu

    1/8/26 5:30:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective December 5th, 2025, to a non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 200,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The award was granted as an induceme

    12/9/25 5:30:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Gossamer Bio from Outperform to Market Perform and set a new price target of $1.00

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hasnain Faheem was granted 280,000 shares, increasing direct ownership by 50% to 837,793 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    1/5/26 4:40:16 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO/CFO Giraudo Bryan was granted 115,750 shares, increasing direct ownership by 42% to 389,737 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    1/5/26 4:39:34 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Smith Robert Paul Jr was granted 93,750 shares, increasing direct ownership by 56% to 260,898 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    1/5/26 4:38:59 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/24/24 5:52:18 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/20/24 8:21:38 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    8/2/24 6:30:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing

    11/5/25 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

    - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $213 million as of June 30, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. Gossame

    8/5/25 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Leadership Updates

    Live Leadership Updates

    View All

    Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

    - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

    12/5/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

    11/29/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

    10/3/23 4:08:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care